These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1123 related articles for article (PubMed ID: 31541034)
1. Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes. Carlos Dos Santos J; Beijer B; Bauder-Wüst U; Schäfer M; Leotta K; Eder M; Benešová M; Kleist C; Giesel F; Kratochwil C; Kopka K; Haberkorn U; Mier W J Nucl Med; 2020 Jan; 61(1):70-79. PubMed ID: 31541034 [TBL] [Abstract][Full Text] [Related]
2. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127 [TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
4. Preclinical Evaluation of a High-Affinity Sarcophagine-Containing PSMA Ligand for Kelly JM; Ponnala S; Amor-Coarasa A; Zia NA; Nikolopoulou A; Williams C; Schlyer DJ; DiMagno SG; Donnelly PS; Babich JW Mol Pharm; 2020 Jun; 17(6):1954-1962. PubMed ID: 32286841 [TBL] [Abstract][Full Text] [Related]
5. Basaco Bernabeu T; Mansi R; Del Pozzo L; Zanger S; Gaonkar RH; McDougall L; De Rose F; Jaafar-Thiel L; Herz M; Eiber M; Ulaner GA; Weber WA; Fani M J Nucl Med; 2024 Sep; 65(9):1427-1434. PubMed ID: 39025646 [TBL] [Abstract][Full Text] [Related]
6. In Vitro and In Vivo Characterization of an Lütje S; Franssen GM; Herrmann K; Boerman OC; Rijpkema M; Gotthardt M; Heskamp S J Nucl Med; 2019 Jul; 60(7):1017-1022. PubMed ID: 30655329 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and pre-clinical evaluation of a new class of high-affinity Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991 [TBL] [Abstract][Full Text] [Related]
8. Design and Preclinical Evaluation of an Albumin-Binding PSMA Ligand for Umbricht CA; Benešová M; Hasler R; Schibli R; van der Meulen NP; Müller C Mol Pharm; 2018 Dec; 15(12):5556-5564. PubMed ID: 30376344 [TBL] [Abstract][Full Text] [Related]
9. Targeting PSMA with a Cu-64 Labeled Phosphoramidate Inhibitor for PET/CT Imaging of Variant PSMA-Expressing Xenografts in Mouse Models of Prostate Cancer. Nedrow JR; Latoche JD; Day KE; Modi J; Ganguly T; Zeng D; Kurland BF; Berkman CE; Anderson CJ Mol Imaging Biol; 2016 Jun; 18(3):402-10. PubMed ID: 26552656 [TBL] [Abstract][Full Text] [Related]
10. A PSMA Ligand Labeled with Cobalt-55 for PET Imaging of Prostate Cancer. Dam JH; Olsen BB; Baun C; Høilund-Carlsen PF; Thisgaard H Mol Imaging Biol; 2017 Dec; 19(6):915-922. PubMed ID: 28924629 [TBL] [Abstract][Full Text] [Related]
11. Preclinical Evaluation and Pilot Clinical Study of Al Liu T; Liu C; Xu X; Liu F; Guo X; Li N; Wang X; Yang J; Yang X; Zhu H; Yang Z J Nucl Med; 2019 Sep; 60(9):1284-1292. PubMed ID: 30796170 [TBL] [Abstract][Full Text] [Related]
12. Refined Chelator Spacer Moieties Ameliorate the Pharmacokinetics of PSMA-617. Dos Santos JC; Schäfer M; Bauder-Wüst U; Beijer B; Eder M; Leotta K; Kleist C; Meyer JP; Dilling TR; Lewis JS; Kratochwil C; Kopka K; Haberkorn U; Mier W Front Chem; 2022; 10():898692. PubMed ID: 36017165 [TBL] [Abstract][Full Text] [Related]
13. Development of Potemkin R; Strauch B; Kuwert T; Prante O; Maschauer S Mol Pharm; 2020 Mar; 17(3):933-943. PubMed ID: 32011889 [TBL] [Abstract][Full Text] [Related]
14. Lee BS; Chu SY; Jung WJ; Jeong HJ; Lee K; Kim MH; Kim MH; Chi DY; Ahn H; Lee YJ; Lee KC; Lim SM Prostate; 2020 Dec; 80(16):1383-1393. PubMed ID: 32960990 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer. Schottelius M; Wurzer A; Wissmiller K; Beck R; Koch M; Gorpas D; Notni J; Buckle T; van Oosterom MN; Steiger K; Ntziachristos V; Schwaiger M; van Leeuwen FWB; Wester HJ J Nucl Med; 2019 Jan; 60(1):71-78. PubMed ID: 30237214 [TBL] [Abstract][Full Text] [Related]
17. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen. Elsässer-Beile U; Reischl G; Wiehr S; Bühler P; Wolf P; Alt K; Shively J; Judenhofer MS; Machulla HJ; Pichler BJ J Nucl Med; 2009 Apr; 50(4):606-11. PubMed ID: 19289418 [TBL] [Abstract][Full Text] [Related]
18. Development of a Ga-68 labeled PET tracer with short linker for prostate-specific membrane antigen (PSMA) targeting. Moon SH; Hong MK; Kim YJ; Lee YS; Lee DS; Chung JK; Jeong JM Bioorg Med Chem; 2018 May; 26(9):2501-2507. PubMed ID: 29655611 [TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of 86Y-labeled inhibitors of prostate-specific membrane antigen for dosimetry estimates. Banerjee SR; Foss CA; Pullambhatla M; Wang Y; Srinivasan S; Hobbs RF; Baidoo KE; Brechbiel MW; Nimmagadda S; Mease RC; Sgouros G; Pomper MG J Nucl Med; 2015 Apr; 56(4):628-34. PubMed ID: 25722448 [TBL] [Abstract][Full Text] [Related]
20. PET Imaging of HER2-Positive Tumors with Cu-64-Labeled Affibody Molecules. Qi S; Hoppmann S; Xu Y; Cheng Z Mol Imaging Biol; 2019 Oct; 21(5):907-916. PubMed ID: 30617730 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]